Cochrane Review Group
ENT
76 systematic reviews in ENT ask 806 questions. 36.4% have no studies to answer them, 30.3% rest on very low certainty evidence and 11.5% reach moderate or high certainty.
Reviews
76
Questions
806
current versions
No studies
36.4%
Moderate or high
11.5%
No studies 293 · 36.4%Ungraded 6 · 0.7%Very low 244 · 30.3%Low 170 · 21.1%Moderate 85 · 10.5%High 8 · 1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Betahistine vs placebo/no treatment Improvement in vertigo frequency · Ménière’s disease Systemic pharmacological interventions for Ménière’s disease (2023) · Cochrane | RR 1.5 [0.98, 2.29] | 1 study · 70 participants | Very low |
Betahistine vs placebo/no treatment Improvement in vertigo frequency · Ménière’s disease Systemic pharmacological interventions for Ménière’s disease (2023) · Cochrane | RR 1.11 [0.93, 1.32] | 1 study · 62 participants | Very low |
Betahistine vs placebo/no treatment Vertigo global score · Ménière’s disease Systemic pharmacological interventions for Ménière’s disease (2023) · Cochrane | no estimate extracted | 1 study · 34 participants | Very low |
Betahistine vs placebo/no treatment Change in vertigo frequency · Ménière’s disease Systemic pharmacological interventions for Ménière’s disease (2023) · Cochrane | no estimate extracted | 2 studies · 117 participants | Very low |
Betahistine vs placebo/no treatment Change in vertigo frequency · Ménière’s disease Systemic pharmacological interventions for Ménière’s disease (2023) · Cochrane | no estimate extracted | 1 study · 214 participants | Very low |
Betahistine vs placebo/no treatment Serious adverse events · Ménière’s disease Systemic pharmacological interventions for Ménière’s disease (2023) · Cochrane | RR 1.2 [0.63, 2.29] | 1 study · 220 participants | Very low |
Diuretic vs placebo/no treatment Improvement in vertigo frequency · Ménière’s disease Systemic pharmacological interventions for Ménière’s disease (2023) · Cochrane | RR 1.69 [1.13, 2.53] | 1 study · 70 participants | Very low |
Diuretic vs placebo/no treatment Change in vertigo frequency · Ménière’s disease Systemic pharmacological interventions for Ménière’s disease (2023) · Cochrane | no estimate extracted | 1 study · 220 participants | Very low |
Beta‐blockers vs placebo Improvement in vertigo · people with vestibular migraine Pharmacological interventions for prophylaxis of vestibular migraine (2023) · Cochrane | no estimate extracted | NR | No studies |
Beta‐blockers vs placebo Serious adverse events · people with vestibular migraine Pharmacological interventions for prophylaxis of vestibular migraine (2023) · Cochrane | RR 0.63 [0.24, 1.67] | 1 study · 121 participants | Very low |
Calcium channel blockers vs no intervention Improvement in vertigo severity · people with vestibular migraine Pharmacological interventions for prophylaxis of vestibular migraine (2023) · Cochrane | RR 1.45 [1.01, 2.07] | 1 study · 48 participants | Very low |
Calcium channel blockers vs no intervention Improvement in vertigo frequency · people with vestibular migraine Pharmacological interventions for prophylaxis of vestibular migraine (2023) · Cochrane | RR 1.65 [0.8, 3.41] | 1 study · 23 participants | Very low |